Schedule 13G ownership disclosure

Halozyme Therapeutics Inc

Security class unavailable · CUSIP: 40637H109

Event date: Unavailable

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
14,003,155
Percent of class
9.5500%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-20-013287
Form type
SC 13G/A
Filer
HALOZYME THERAPEUTICS, INC.
CIK
CIK 1159036
Filed
Feb 10, 2020
Reporting period
—
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub